Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Phase I Study of INT-1868 Tablets in Healthy Adult Participants (INT-1868-I101) (INT-1868-I101)

10 listopada 2026 zaktualizowane przez: Innatus Therapeutics (Shanghai) Co., Ltd.

A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, and Food-effect Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-1868 in Healthy Adult Participants

A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INT-1868 Tablets in Healthy Adult Participants.

  • Primary Objectives:

    1. To evaluate the safety and tolerability of INT-1868 tablets after single and multiple doses in healthy adult participants;

  • Secondary Objectives:

    1. To evaluate the PK characteristics of INT-1868 tablets after single and multiple doses in healthy adult participants; 2. To evaluate the effect of food on the PK characteristics of INT-1868 tablets;

  • Other Objectives:

    1. To evaluate the PD characteristics of INT-1868 tablets after single and multiple doses in healthy adult participants;
    2. To evaluate the PK characteristics of INT-1868 tablet metabolites (if applicable) after single and multiple doses in healthy adult participants;
    3. To assess the effect of INT-1868 tablets on C-QTc;
    4. To preliminarily evaluate the metabolic characteristics of INT-1868 tablets in humans.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

92

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chiny
        • Beijing Municipality -No. 101, Luyuan East Road, Tongzhou District, Beijing, China
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 45 lat (Dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Participants fully understand the purpose, nature, methods, and potential adverse reactions of the trial, voluntarily participate and sign the written Informed Consent Form, and are able to comply with the Protocol requirements to complete the study;
  • Healthy trial participants aged 18 to 45 years (inclusive), regardless of gender (the proportion of males and females in each group shall not be less than 1/3);
  • Body Mass Index (BMI: weight [kg]/height [m2) between 18.5 and 26.0 kg/m2Within the range (including boundary values), participants body weight ≥45 kg for females and ≥50 kg for males;
  • The investigator determines that the participants is in good general health (assessed by medical history, surgical history, physical examination, vital signs, laboratory tests, electrocardiogram, etc., with no evidence of active or chronic cyclic diseases);
  • Female participants of childbearing potential must agree to use effective contraception throughout the study period and for at least 90 days after the last dose; all female participants must have no plan for pregnancy or egg donation from the start of the study until at least 90 days after the last dose;
  • Males of reproductive potential must agree to practice abstinence or use effective contraception throughout the study period and for at least 90 days after the last dose; all male trial participants must have no plan to donate sperm throughout the study period and for at least 90 days after the last dose.

Exclusion Criteria:

  • As assessed by the Investigator, presence ofClinically significantHistory of diseases, including but not limited to those of the gastrointestinal system, cardiovascular system, musculoskeletal system, endocrine system, blood and lymphatic system, kidneys, liver, respiratory system, nervous system, immune system, reproductive system, and lipid metabolism disorders; or any clinically significant abnormal results in physical examination, vital signs, ECG, or laboratory tests during the screening period as determined by the Investigator;

  • History of hospitalization or major surgery within the 6 months prior to screening, planned surgery during the study period, or history of bariatric surgery;

  • History of gastrointestinal, hepatic, or renal diseases that may affect drug absorption or metabolism;

  • History of hypertrophic scarring (keloid constitution), or skin abnormalities unsuitable for skin sample collection, or history of allergy to anesthetics or antibiotics (limited to trial participants intended for enrollment in the MAD study);

  • Participants with abnormal swallowing function, unable to swallow oral formulations normally;

  • During the screening period, the presence of any of the following electrocardiogram (ECG) abnormalities:

    1. Any ECG parameters outside the normal range or abnormal findings considered clinically significant by the Investigator;
    2. Any electrocardiogram (ECG) abnormalities (e.g., difficulty in measuring QT interval, conduction abnormalities) that the Investigator considers may affect the interpretation of cardiac safety and/or interfere with the assessment of adverse events after dosing;
    3. QT interval corrected by the Fridericia formula (QTcF) ≥450 ms for males and ≥460 ms for females;
  • Resting heart rate <50 beats per minute (bpm) or >100 beats per minute (bpm) during the screening period;

  • Systolic blood pressure ≥140 mmHg or <90 mmHg, and/or diastolic blood pressure ≥90 mmHg or <50 mmHg during the screening period;

  • Renal function judged by the Investigator based on clinical laboratory results, with an estimated Glomerular Filtration Rate (eGFR) <90 mL/min/1.73 m² calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, or signs of renal impairment;

  • Presence of active liver disease or unexplained abnormalities in liver function tests (LFTs) during the screening period, defined as: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), γ-Glutamyl Transferase (γ-GGT), Alkaline Phosphatase (ALP), or Total/Direct Bilirubin levels exceeding the Upper Limit of the Reference Range (ULRR); or participants diagnosed with Gilbert's syndrome (constitutional non-hemolytic jaundice) are not allowed to participate in the study;

  • Participants with positive results for any of the following tests: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody, or Treponema pallidum antibody;

  • Trial participants with active tuberculosis, with positive tuberculosis screening results during the screening period (if applicable);

  • Patients with malignant tumors (including those cured after previous illness);

  • Participants who experience acute illness during the screening period;

  • Presence of clinically significant infections, known inflammatory diseases, or a history of clinically significant infections within 14 days before the first dose administration;

  • Known or suspected history of drug abuse within the 2 years prior to screening, or history of alcohol abuse within the 90 days prior to screening;

  • Daily smoking of more than 5 cigarettes within the 6 months prior to screening, and inability to stop smoking and using nicotine products throughout the trial period;

  • Positive results for alcohol testing or urine drug abuse screening during the screening period;

  • Alcohol consumption exceeding 14 units per week within the 6 months prior to screening (1 unit of alcohol ≈ 360 mL of beer, 45 mL of spirits with 40% alcohol content, or 150 mL of wine), or inability to abstain from alcohol during the trial;

  • Alcohol consumption within 72 hours prior to the first dose;

  • Participation in any clinical study of Investigational Medicinal Product, device, biologic, or other investigational formulation within 30 days prior to the first dose (or within 5 half-lives, whichever is longer, if applicable);

  • Use of any medication (including prescription drugs, over-the-counter drugs, traditional Chinese herbal medicines, etc., but excluding anesthetics and antibiotics permitted by the protocol for skin tissue sample collection in MAD study participants) or health supplements within 14 days prior to the first dose (or within 7 half-lives, whichever is longer);

  • Vaccination within 30 days prior to the first dose, or planned vaccination during the study period;

  • Consumption of food or beverages containing caffeine, xanthines, or grapefruit-related components (e.g., coffee, strong tea, chocolate, etc.) within 48 hours prior to the first dose;

  • Total blood loss or blood donation exceeding 400 mL, plasma donation, or transfusion of blood and blood components within 30 days prior to the first dose; donation of bone marrow or peripheral stem cells within 90 days prior to the first dose;

  • Poor venous access that fails to meet the requirements for Pharmacokinetics blood sample collection; history of intolerance to blood collection during previous phlebotomy or blood donation;

  • Known hypersensitivity to INT-1868 or any of its excipients, or a history of unexplained weight loss, food allergies, or intolerance to specific foods;

  • Females who are pregnant or lactating, or females of childbearing potential who have engaged in unprotected sexual intercourse within 14 days prior to the first dose, or females with a positive pregnancy test during the screening period;

  • Participants who are a member of the investigator, site personnel, sponsor staff, or their relatives;

  • Participants who are unwilling to comply with trial restrictions and related requirements (e.g., dietary contraindications, inability to adhere to the trial-specified diets, high-fat meals, etc.);

  • The investigator considers it inappropriate for the 29) participants to participate in this study due to scientific reasons, compliance reasons, subject safety, or any other reasons.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Single Ascending Dose from 2.5 mg to 300 mg

Single Ascending Dose

Escalating doses of 2.5, 10, 30, 100, 200, 300 mg of INT-1868; Single dose administration; Oral administration

Escalating doses of 10, 30, 100 mg, 200 mg of INT-1868; QD for 14 days; Oral administration

100 mg INT-1868; Dosing on Day 1 (first dose) and Day 11 (second dose);Oral administration

Eksperymentalny: Multiple Ascending Dose: 10 mg to 200mg

QD for 14 days;

Escalating doses of 2.5, 10, 30, 100, 200, 300 mg of INT-1868; Single dose administration; Oral administration

Escalating doses of 10, 30, 100 mg, 200 mg of INT-1868; QD for 14 days; Oral administration

100 mg INT-1868; Dosing on Day 1 (first dose) and Day 11 (second dose);Oral administration

Eksperymentalny: Food Effect: 100 mg

Escalating doses of 2.5, 10, 30, 100, 200, 300 mg of INT-1868; Single dose administration; Oral administration

Escalating doses of 10, 30, 100 mg, 200 mg of INT-1868; QD for 14 days; Oral administration

100 mg INT-1868; Dosing on Day 1 (first dose) and Day 11 (second dose);Oral administration

Komparator placebo: Placebo

Placebo for SAD, MAD and Food Effect

INT-1868 Placebo;PO

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Adverse events(AEs)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

The incidence, severity and types of AES

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Laboratory tests: Complete Blood Count
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Including complete blood count, blood biochemistry, coagulation function, and urinalysis

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Physical examination
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Including general condition (skin and lymph nodes), head (eyes, ears, nose, and throat), neck (thyroid gland), chest (lungs and heart), abdomen, spine and extremities, and nervous system

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Treatment-emergent potentially clinically significant abnormalities in vital signs:blood pressure (mmHg)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Blood pressure (mmHg)

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Treatment-emergent potentially clinically significant abnormalities in vital signs:pulse rate (bpm)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Pulse rate (bpm)

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Treatment-emergent potentially clinically significant abnormalities in vital signs: respiratory rate (brpm)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Respiratory rate (brpm)

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Treatment-emergent potentially clinically significant abnormalities in vital signs: body temperature (℃)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Body temperature (℃)

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: heart rate (bpm)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Heart rate (bpm)

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: PR Interval (milliseconds)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

PR Interval (milliseconds)

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: QRS duration (milliseconds)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

QRS duration (milliseconds)

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: QT interval (milliseconds)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

QT interval (milliseconds)

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: QTc (milliseconds)
Ramy czasowe: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

QTc (milliseconds)

SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Pharmacokinetics parameter: Cmax of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Maximum plasma concentration

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: Tmax of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Time to reach maximum plasma concentration

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: AUC0-t of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Area under the concentration-time curve from time 0 to the time of the last measurable concentration (t)

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: AUC0-24 of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Area under the plasma concentration-time curve of the investigational product from 0 to 24 hours

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: AUC0-inf of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Area under the plasma concentration-time curve of the investigational product from time 0 to infinity

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: t1/2 of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Terminal elimination half-life

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: λz of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Terminal elimination rate constant

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: CL/F of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Apparent clearance

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: Vd/F of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Apparent volume of distribution

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: tlag of INT-1868
Ramy czasowe: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)

Lag time

SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: Cmin,ss of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Minimum plasma concentration at steady state

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Cmax,ss of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Maximum plasma concentration at steady state

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Css,avg of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Average plasma concentration at steady state

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: AUC0-t of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Area under the plasma concentration-time curve of the investigational product during the dosing interval (t)

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Tmax of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Time to reach maximum plasma concentration at steady state

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: λz of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Terminal elimination rate constant

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: t1/2 of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours(29 blood sampling time points)

Terminal elimination half-life

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours(29 blood sampling time points)
Pharmacokinetics parameter: Rac(Cmax)of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Accumulation ratio based on Cmax

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Rac(AUC)of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Accumulation ratio based on AUC

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: CLss/F of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Apparent clearance at steady state

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Vz/F of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)

Apparent volume of distribution at steady state

MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Urinary pharmacokinetic parameters, including Ae and CumAe0-t, Fe, and CumFe0-tand CLr
Ramy czasowe: SAD: pre-dose (-12 to 0 hours) and post-dose 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 24-48 hours, and 48-72 hours.

Amount of drug excreted in urine (Ae), cumulative amount excreted in urine (CumAe0-t), urinary excretion fraction (Fe), cumulative excretion fraction (CumFe0-t) and renal clearance (CLr)

SAD: pre-dose (-12 to 0 hours) and post-dose 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 24-48 hours, and 48-72 hours.
Fecal pharmacokinetic parameters, including Ae and CumAe0-t, Fe, and CumFe0-t
Ramy czasowe: SAD: pre-dose (-24 to 0 hours) and post-dose 0-24 hours, 24-48 hours and 48-72 hours

Amount of drug excreted in feces (Ae), cumulative amount excreted in feces (CumAe0-t), fecal excretion fraction (Fe), and cumulative excretion fraction (CumFe0-t)

SAD: pre-dose (-24 to 0 hours) and post-dose 0-24 hours, 24-48 hours and 48-72 hours

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Pharmacodynamics parameter: STAT6 of INT-1868
Ramy czasowe: SAD:pre-dose (within 1 hour) and post-dose from Day 1 to Day 14 MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 38

Signal transducer and activator of transcription 6 (STAT6) in peripheral blood

SAD:pre-dose (within 1 hour) and post-dose from Day 1 to Day 14 MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 38
Pharmacodynamics parameter: TARC of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28

Thymus and activation-regulated chemokine

MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
Pharmacodynamics parameter: IgE of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28

Immunoglobulin E

MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
Pharmacodynamics parameter: Eotaxin-3 of INT-1868
Ramy czasowe: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
Pharmacodynamics parameter: STAT6 of INT-1868
Ramy czasowe: MAD: From Day-1 to Day 28

STAT6 in skin tissue

MAD: From Day-1 to Day 28

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

9 listopada 2026

Zakończenie podstawowe (Szacowany)

17 czerwca 2027

Ukończenie studiów (Szacowany)

17 lipca 2027

Daty rejestracji na studia

Pierwszy przesłany

5 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 listopada 2026

Pierwszy wysłany (Rzeczywisty)

17 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj